SCHEMBL21045830

SCHEMBL21045830

C[SiH](C)OC([C@H]1CNCCN1C(=O)OC(C)(C)C)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.39
NR1H2 P55055 2/20 0.31
NR1H3 Q13133 2/20 0.31
HSD17B10 Q99714 1/20 0.30
USP2 O75604 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28449177 1.00 PARP1 (0.39) PARP1NR1H2NR1H3HSD17B10USP2
SCHEMBL21045726 1.00 PARP1 (0.39) PARP1NR1H2NR1H3HSD17B10USP2
SCHEMBL26105636 1.00 PARP1 (0.39) PARP1NR1H2NR1H3HSD17B10USP2
SCHEMBL22367024 0.86
SCHEMBL3618472 0.80 PARP1 (0.43) PARP1NR1H2NR1H3HSD17B10USP2
SCHEMBL873224 0.80 PARP1 (0.43) PARP1NR1H2NR1H3HSD17B10USP2
SCHEMBL1861184 0.80 NR1H2 (0.34) NR1H2NR1H3HSD17B10USP2SMN1; SMN2
SCHEMBL63799 0.80 PARP1 (0.43) PARP1NR1H2NR1H3HSD17B10USP2
SCHEMBL23579211 0.79 PARP1 (0.42) PARP1NR1H2NR1H3HSD17B10USP2
SCHEMBL31435138 0.79 PARP1 (0.42) PARP1NR1H2NR1H3HSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752499-B1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INT (DE) 2024-03-27 EP disclosed
CN-111770918-B Inhibitors of TRPC6 勃林格殷格翰国际公司 2024-02-27 CN disclosed
US-RE49699-E1 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-17 US disclosed
CN-111527078-B Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors 勃林格殷格翰国际公司 2023-06-02 CN disclosed
EP-3700902-B1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INT (DE) 2023-03-08 EP disclosed
US-11485740-B2 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-11-01 US disclosed
EP-3786160-B1 PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2022-07-13 EP disclosed
US-20210163449-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-06-03 US disclosed
EP-3786160-A1 PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS Boehringer Ingelheim International GmbH (DE) 2021-03-03 EP disclosed
US-10889568-B2 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-01-12 US disclosed
US-20200399282-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-12-24 US disclosed
EP-3752499-A1 INHIBITORS OF TRPC6 Boehringer Ingelheim International GmbH (DE) 2020-12-23 EP disclosed
CN-111770918-A Inhibitors of TRPC6 勃林格殷格翰国际公司 2020-10-13 CN disclosed
US-10800757-B2 Inhibitors of TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-13 US disclosed
CN-111527078-A Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors 勃林格殷格翰国际公司 2020-08-11 CN disclosed
WO-2019158572-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-08-22 WO disclosed
US-20190169168-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-06 US disclosed
US-20190169167-A1 INHIBITORS OF TRPC6 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399282-A1 INHIBITORS OF TRPC6 TRPC6, TRPC1, TRPC4 PARP1 1809/4885NR1H2 2444/4885NR1H3 3016/4885
US-20190169168-A1 INHIBITORS OF TRPC6 TRPC6, TRPC1, TRPC7 PARP1 3686/4885NR1H2 1608/4885NR1H3 2166/4885
US-20210163449-A1 INHIBITORS OF TRPC6 TRPC6, TRPC1, TRPC7 PARP1 3445/4885NR1H2 1649/4885NR1H3 2253/4885
US-10889568-B2 Inhibitors of TRPC6 TRPC6, TRPC1, TRPC7 PARP1 3686/4885NR1H2 1608/4885NR1H3 2166/4885
US-11485740-B2 Inhibitors of TRPC6 TRPC6, TRPC1, TRPC4 PARP1 1809/4885NR1H2 2444/4885NR1H3 3016/4885
US-20190169167-A1 INHIBITORS OF TRPC6 TRPC6, TRPC1, TRPC7 PARP1 3686/4885NR1H2 1608/4885NR1H3 2166/4885
US-10800757-B2 Inhibitors of TRPC6 TRPC6, TRPC1, TRPC7 PARP1 3686/4885NR1H2 1608/4885NR1H3 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.